Search results for " Colitis."

showing 10 items of 292 documents

5-Aminosalicylsäure-assoziierte Pankreatitis

2008

Acute pancreatitis with severe belt-like upper abdominal pain developed within 1-4 weeks of starting medication in three patients (29-year-old man with ulcerative colitis; 43-year-old woman and 22-year-old woman with Crohn's disease) treated, for the first time, with 5-aminosalicylic acid (mesalazine), 500 mg three times daily. Concentrations of lipase initially were 545, 1182 and 3000 U/l, and of amylase 243, 449 and 129 U/l, respectively. Symptoms receded within a few hours after the drug had been discontinued, enzyme levels returning to normal in the course of the next 2-3 weeks. On repeating the drug in two of the patients, in lower dosage, the pancreatitis recurred within a few days. T…

Drugmedicine.medical_specialtybiologybusiness.industrymedia_common.quotation_subjectGeneral Medicinemedicine.diseaseGastroenterologyUlcerative colitischemistry.chemical_compoundMesalazinechemistryInternal medicineUpper abdominal painbiology.proteinMedicinePancreatitisAcute pancreatitisAmylaseLipasebusinessmedia_commonDMW - Deutsche Medizinische Wochenschrift
researchProduct

Guanosine prevents nuclear factor-κB nuclear translocation ameliorating experimental colitis in rats

2018

Background inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are prevalent and debilitating health problems worldwide. Due to the adverse effects of classical treatment for IBD, therapeutic options and approaches for these diseases continue to evolve. Guanosine, a guanine-based purine, is an extracellular signalling molecule that seems to exert anti-inflammatory and antioxidative effects in several in vivo and in vitro injury models. The aim of the present study was to investigate whether exogenous guanosine may have protective effects on 2,4-dinitrobenzene sulfonic acid (DNBS)-induced Colitis in rat. Methods Experimental Colitis was induced by …

EXPERIMENTAL COLITIS GUANOSINE INFLAMMATORY BOWEL DISEASESettore BIO/09 - Fisiologia
researchProduct

IL-12 family members in experimental colitis

2008

Interleukin (IL)-12 p35/p40 is a heterodimeric cytokine that plays an important role in T helper (Th) cell polarization and Th1 T-cell differentiation. Recent findings have shown that both p35 and p40 can form other cytokines with different proteins (IL-23: p19/p40; IL-35: p35/EBI3). Furthermore, the cytokine IL-27 (EBI3/p28) has been identified as a member of the IL-12 family. Here, we discuss the recent findings on the role of IL-12 family members in experimental colitis. In particular, the role of IL-23 as a master regulator of effector T-cell activation is highlighted. These findings have important implications for the design of new therapeutic approaches in chronic intestinal inflammat…

EffectorT-Lymphocytesmedicine.medical_treatmentImmunologyInterleukinMaster regulatorExperimental colitishemic and immune systemsEBI3BiologyColitisInflammatory Bowel DiseasesInterleukin-12CytokineIntestinal inflammationImmunologyInterleukin 12medicineAnimalsHumansImmunology and AllergySignal TransductionMucosal Immunology
researchProduct

Does uremic enterocolitis exist?

1981

In rats a severe but compensated chronic renal insufficiency was induced by stepwise 9/10 nephrectomy. Despite this severe chronic renal insufficiency we observed no relevant pathological changes in the intestinal mucosa. In particular, we found no evidence of mucosal erosions, ulceration or pseudomembranous colitis, findings which are traditionally thought to be characteristic of the uremic state. This was also true of those animals dying prematurely from uremia. Thus serious doubts arise about the existence of “uremic enterocolitis”, doubts which also proved justified after a critical review of the literature on human pathology.

EnterocolitisPathologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPseudomembranous colitismedicine.diseaseIntestinal absorptionNephrectomyUremiaIntestinal mucosamedicinemedicine.symptombusinessHuman PathologyPathologicalVirchows Archiv B Cell Pathology Including Molecular Pathology
researchProduct

Liver infarction in a patient with Clostridium Difficile colitis. A possible connection?

2019

.

Enterocolitismedicine.medical_specialtyFatal outcomebusiness.industryGastroenterologyClostridium difficileLiver infarctionGastroenterologyConnection (mathematics)Clostridium Difficile ColitisInternal medicinemedicinemedicine.symptombusinessJournal of Gastrointestinal and Liver Diseases
researchProduct

Inflammatory Bowel Diseases

1979

The endoscopic aspects of an inflammatory colon disease do not permit the differentiation of a nonspecific proctitis from a bacterial enterocolitis and an ulcerative proctitis.

Enterocolitismedicine.medical_specialtybusiness.industryInflammatory Bowel DiseasesDiseasePseudomembranous colitismedicine.diseaseGastroenterologyUlcerative colitisdigestive system diseasesIschemic colitisUlcerative proctitisInternal medicineMedicinemedicine.symptombusinessProctitis
researchProduct

Elevated serum eotaxin levels in patients with inflammatory bowel disease.

2002

OBJECTIVE: Eotaxin is a recently characterized chemokine with potent and selective chemotactic activity for eosinophils. Previous studies indicating that eosinophils accumulate and become activated in inflammatory bowel disease (IBD) led us to hypothesize that eotaxin is potentially involved in the pathophysiology of IBD and, therefore, that eotaxin would be increased in the serum of patients with IBD. The objective of this study was to test those assumptions. METHODS: We investigated 72 patients with IBD, 35 with ulcerative colitis, and 37 with Crohn’s disease. A total of 27 patients had active and 45 inactive disease; 26 were receiving corticosteroids. Eotaxin serum levels were determined…

EotaxinAdultChemokine CCL11Adolescentmedicine.medical_treatmentInflammatory bowel diseaseSeverity of Illness IndexPathogenesisLeukocyte CountPrednisoneReference ValuesmedicineHumansAgedHepatologybusiness.industryGastroenterologyrespiratory systemEosinophilMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisdigestive system diseasesPathophysiologyEosinophilsmedicine.anatomical_structureCytokineChemokines CCImmunologyColitis Ulcerativebusinessmedicine.drugThe American journal of gastroenterology
researchProduct

P114 A screening tool for the early diagnosis of extraintestinal manifestations in inflammatory bowel disease: the EMAIL questionnaire

2020

Abstract Background Data on prevalence of extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD) range from 6% up to 47%. Recently, several red flags and questionnaires have been proposed for early diagnosis of articular manifestations. Our aim was to analyse the prevalence of EIMs in a single-centre prospective cohort, using a comprehensive questionnaire developed by our group to detect all EIMs (EMAIL questionnaire). Methods Patients with IBD attending our Clinic from November 2017 to January 2019 were interviewed using a two-part questionnaire, the first part for clinical-demographic data and the second part for EIMs. Patients positive to screening were referred for mu…

Erythema nodosumAnkylosing spondylitismedicine.medical_specialtyCrohn's diseasebusiness.industryGastroenterologySacroiliitisGeneral Medicinemedicine.diseaseUlcerative colitisInflammatory bowel diseaseInternal medicinePsoriasismedicinebusinessPyoderma gangrenosumJournal of Crohn's and Colitis
researchProduct

Oral manifestations of gastrointestinal disorders

2017

Indexación: Scopus. Backgroud: A considerable number of gastrointestinal disorders (GIDs) of varied nature (inflammatory, infectious, genetic and other etiology) may produce alterations in the hard and soft oral tissues. Among these are Crohn's disease, ulcerative colitis, celiac and gastroesophageal reflux disease. Material and Methods: Article search was done using the National library of medicine (PubMed) database using different search terms and analyzed according to their importance. Results: A large variety of GIDs can give rise to oral lesions, including: RAS like ulceration, mucosal tags, cobblestoning, mucogingivitis, labial and facial swelling, pyostomatitis vegetans, disgeusia an…

Facial swellingmedicine.medical_specialtyOral lesionsSigns and symptomsReviewDiseaseGastrointestinal disorders03 medical and health sciences0302 clinical medicineQuality of lifeOral mucosal disordersmedicineGeneral DentistryOral Medicine and Pathologybusiness.industry030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ulcerative colitisDermatologystomatognathic diseasesSearch termsUNESCO::CIENCIAS MÉDICASEtiology030211 gastroenterology & hepatologymedicine.symptombusinessPyostomatitis vegetans
researchProduct

Beneficial Effect of Shikonin on Experimental Colitis Induced by Dextran Sulfate Sodium in Balb/C Mice

2012

[EN] The naphthoquinone shikonin, a major component of the root of Lithospermum erythrorhizon, now is studied as an anti-inflammatory agent in the treatment of ulcerative colitis (UC). Acute UC was induced in Balb/C mice by oral administration of 5% dextran sodium sulfate (DSS). The disease activity index was evaluated, and a histologic study was carried out. Orally administered shikonin reduces induced UC in a dose-dependent manner, preventing the shortening of the colorectum and decreasing weight loss by 5% while improving the appearance of feces and preventing bloody stools. The disease activity index score was much lower in shikonin-treated mice than in the colitic group, as well as the…

FarmacologiaArticle SubjectPolymorphonuclear leukocytesNF-KAPPA-BActivationIntestinal inflammationPharmacologyInflammatory bowel diseaseBALB/cchemistry.chemical_compoundExperimental Murine ColitisOral administrationWeight lossInflammatory-bowel-diseasemedicineAntisense oligonucleotideAcid-induced colitisbiologybusiness.industrylcsh:Other systems of medicineLithospermum erythrorhizonbiology.organism_classificationNFKB1medicine.diseaselcsh:RZ201-999Ulcerative colitisNaphthoquinoneComplementary and alternative medicinechemistryUlcerative-colitisImmunologyCytokinesmedicine.symptombusinessAntiinflamatorisResearch ArticleEvidence-Based Complementary and Alternative Medicine
researchProduct